|
Daily Medical Update
Sleep Apnea (OSA screening, CPAP adherence)
Saturday, March 7, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Medicina (2025) - Prospective Cohort Meta-analysis
Key Findings
- Across >25,000 participants, OSA was associated with higher incident cardiovascular risk (HR 1.82, 95% CI 1.45-2.28), with a severity gradient up to HR 2.45 in severe OSA.
- CPAP adherence ≥4 hours/night was associated with lower cardiovascular risk (HR 0.76, 95% CI 0.60-0.96), indicating dose-linked benefit.
📋 Practice Implication: Track OSA severity and nightly CPAP hours in follow-up; escalate adherence support when use drops below 4 h/night to reduce downstream CV events.
|
Lancet Respir Med (2025) - Systematic Review/Meta-analysis
Key Findings
- Pooled randomized and confounder-adjusted evidence favored PAP for lower all-cause and cardiovascular mortality versus no treatment.
- Adjusted effect estimates remained in the risk-reduction direction for both all-cause and cardiovascular mortality versus no PAP treatment.
📋 Practice Implication: Prioritize rapid PAP initiation in moderate-to-severe OSA and present treatment as mortality-risk reduction, not only snoring/daytime-sleepiness control.
|
Sleep Med Rev (2025) - Meta-analysis
Key Findings
- Across 74 studies, CPAP significantly improved endothelial function (flow-mediated dilation), a vascular surrogate tied to CV risk reduction.
- CPAP was associated with decreases in total cholesterol, LDL-C, triglycerides, and fasting glucose, with smaller/non-significant pooled changes for HbA1c and insulin endpoints.
📋 Practice Implication: When counseling reluctant patients, link CPAP to measurable vascular and metabolic improvements that align with PCP chronic-disease goals.
|
Sleep (2025) - Meta-analysis
Key Findings
- GLP-1RA treatment reduced AHI by about 9.48 events/hour (95% CI -12.56 to -6.40) and produced substantial weight loss (~11 kg).
- Tirzepatide had larger AHI effects than liraglutide (about -21.86 vs -5.10 events/hour) with associated systolic BP reduction (~4.81 mmHg).
📋 Practice Implication: For obesity-driven OSA (especially PAP-intolerant patients), add anti-obesity pharmacotherapy pathways in collaboration with sleep medicine/endocrinology.
|
Cochrane Database Syst Rev (2025) - Randomized Evidence Review
Key Findings
- Across randomized comparisons, limited-channel pathways produced similar changes in sleepiness and quality-of-life outcomes versus polysomnography-led pathways in suspected OSA.
- Lower-resource testing strategies improve throughput and can reduce time-to-diagnosis where lab PSG capacity is constrained.
📋 Practice Implication: Adopt a tiered pathway: use home/limited-channel studies first for uncomplicated high-probability OSA, reserving lab PSG for complex or inconclusive cases.
|
Sleep Med Rev (2025) - Systematic Review/Meta-analysis
Key Findings
- Patients with OSA had higher odds of respiratory adverse events during ambulatory procedural sedation (OR 1.65, 95% CI 1.03-2.66).
- OSA also increased odds of requiring airway intervention (OR 3.28, 95% CI 1.43-7.51), while cardiovascular event odds were not significantly different.
📋 Practice Implication: Embed OSA status in pre-procedure clearance notes and request enhanced respiratory monitoring plans for outpatient sedation referrals.
|
|
Recent high-level evidence reinforces OSA as a cardiovascular risk condition where treatment intensity and adherence materially influence outcomes. In primary care, the biggest practice shifts are to tighten screening in at-risk adults, monitor CPAP use as a therapeutic target, and integrate obesity pharmacotherapy when weight-driven OSA persists or PAP is poorly tolerated.
|
|